Full Sail Capital LLC reduced its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 17.0% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,499 shares of the company’s stock after selling 715 shares during the period. Full Sail Capital LLC’s holdings in Johnson & Johnson were worth $542,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. GW&K Investment Management LLC bought a new position in Johnson & Johnson in the 4th quarter valued at approximately $35,000. Dark Forest Capital Management LP increased its position in Johnson & Johnson by 1,044.4% in the 4th quarter. Dark Forest Capital Management LP now owns 206 shares of the company’s stock valued at $36,000 after acquiring an additional 188 shares during the period. Ruedi Wealth Management Inc. acquired a new position in shares of Johnson & Johnson during the fourth quarter worth $42,000. Kepos Capital LP bought a new stake in shares of Johnson & Johnson in the fourth quarter worth $45,000. Finally, VitalStone Financial LLC bought a new position in Johnson & Johnson during the 4th quarter worth $52,000. 67.57% of the stock is owned by institutional investors.
Johnson & Johnson Stock Down 0.1 %
Johnson & Johnson stock opened at $173.07 on Thursday. The firm has a market capitalization of $449.80 billion, a price-to-earnings ratio of 35.03, a price-to-earnings-growth ratio of 2.90 and a beta of 0.54. The firm’s fifty day moving average price is $164.21 and its two-hundred day moving average price is $161.13. Johnson & Johnson has a 1-year low of $150.11 and a 1-year high of $181.04. The company has a current ratio of 1.12, a quick ratio of 0.88 and a debt-to-equity ratio of 0.44.
Johnson & Johnson Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 7th. Shareholders of record on Monday, August 28th will be issued a dividend of $1.19 per share. This represents a $4.76 dividend on an annualized basis and a yield of 2.75%. The ex-dividend date is Friday, August 25th. Johnson & Johnson’s dividend payout ratio is 96.36%.
Analyst Ratings Changes
JNJ has been the subject of several recent research reports. Credit Suisse Group increased their price target on Johnson & Johnson from $170.00 to $175.00 and gave the company a “neutral” rating in a research note on Friday, July 21st. Citigroup initiated coverage on shares of Johnson & Johnson in a research report on Tuesday, May 30th. They issued a “buy” rating and a $185.00 price target on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research report on Monday, July 31st. Barclays upped their price target on shares of Johnson & Johnson from $171.00 to $175.00 and gave the company an “equal weight” rating in a research report on Monday, July 24th. Finally, JPMorgan Chase & Co. lifted their price objective on Johnson & Johnson from $175.00 to $180.00 and gave the stock a “neutral” rating in a research report on Friday, July 21st. Eight equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $171.80.
Get Our Latest Analysis on JNJ
Insider Activity
In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 12,465 shares of the stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $160.00, for a total value of $1,994,400.00. Following the completion of the sale, the executive vice president now owns 65,934 shares in the company, valued at approximately $10,549,440. The transaction was disclosed in a document filed with the SEC, which is available at this link. In related news, EVP Kathryn E. Wengel sold 12,465 shares of Johnson & Johnson stock in a transaction on Monday, June 12th. The stock was sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the sale, the executive vice president now directly owns 65,934 shares in the company, valued at $10,549,440. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Peter Fasolo sold 20,000 shares of the business’s stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total value of $3,406,400.00. Following the completion of the transaction, the vice president now directly owns 102,696 shares in the company, valued at approximately $17,491,182.72. The disclosure for this sale can be found here. Insiders sold a total of 47,163 shares of company stock worth $7,928,856 over the last quarter. Insiders own 0.20% of the company’s stock.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Stories
- Five stocks we like better than Johnson & Johnson
- How to Invest in Artificial Intelligence
- 3 Stocks to Buy No Matter Which Way Inflation Moves
- What Are the FAANG Stocks and Are They Good Investments?
- 7 Best Fintech ETFs to Buy Now
- Are Stock Buybacks Good for the Average Investor?
- 2 Alternatives To Tesla (1 Safe, 1 More Risky)
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
